BIOSYNEX
BIOSYNEX SA Extension of the distribution agreement between Credo Diagnostics Biomedical Pte Ltd and BIOSYNEX S.A. BIOSYNEX (ISIN : FR0011005933, Mnémonique :ALBIO), a major player in public health, announces the extension of its partnership with the Singaporean company Credo Diagnostics Biomedical Pte Ltd (“Credo Diagnostics”). The collaboration between the two companies had started at the beginning of the Covid-19 health crisis in March 2020, which eventually led to an agreement to distribute VitaPCRTM systems in France, Belgium, Switzerland and Luxembourg. Founded in 2011, Credo Diagnostics launched the VitaPCRTM in 2019, a revolutionary molecular biology platform capable of detecting infectious pathogens (including the SARS-CoV-2 responsible for Covid-19, influenza and RSV viruses) by Polymerase Chain Reaction (PCR) methodology in only 20 minutes. With its ease of use, VitaPCRTM contributes significantly to the decentralization of tests from centralized labs to private medical laboratories, general hospitals or even directly by nursing staff in clinical departments. In more than two years of partnership, BIOSYNEX has successfully implemented the VitaPCRTM solution in more than 300 sites in France, including private clinical laboratories, hospitals, and remote sites (airports, cruise ships, companies). BIOSYNEX and Credo Diagnostics have recently strengthened their collaboration by signing an exclusivity agreement for an extended territory including the United Kingdom. Thanks to the acquisition of BHR in May 2022, BIOSYNEX now has a direct sales force in the United Kingdom and anticipates a significant deployment of the VitaPCRTM systems in this country which is at the forefront of Point-of-Care diagnostic solutions. In addition, Credo Diagnostics will be releasing a next generation rapid PCR platform, VitaSIRO soloTM based on microfluidic technology that simplifies the entire procedure. The multiplexing capability of the new platform enables the simultaneous viral detection of influenza, SARS-CoV-2 and Respiratory Syncytial Virus (RSV) that cause bronchiolitis. This new respiratory assay was developed with the intention of meeting the diagnostic demand linked to winter respiratory epidemics due to multiple viruses and will strengthen the diagnostics portfolio of Credo Diagnostics. Furthermore, new applications are being developed on this platform and will enable BIOSYNEX to expand its solution offer to existing customers as well as future prospects. Larry Abensur, Chaiman and CEO of BIOSYNEX: “Our collaboration with Credo Diagnostics has greatly contributed to making BIOSYNEX a key player in Covid-19 diagnostics in France. This new agreement is a major step in our partnership because it opens up important commercial development opportunities in this post pandemic period by giving us access to new applications and new territories.” Dr. Winston Wong Jr., Chairman and CEO of Credo Diagnostics: “We are happy with the performances of BIOSYNEXnot only in the areas of the distribution of our products, but the support in other areas of Clinical Performance Studies and generation of scientific reports for our VitaPCR™ platforms. I am looking forward to the introduction of our new VitaSIRO solo™ platforms to their distribution network.”
Next communication : Full-year revenue 2022 : Thursday 19 january 2023, after market.
Press coverage :https://www.biosynex.com/actualites/
CONTACTS Larry Abensur
Regulatory filing PDF file File: CREDO ENGLISH |
| Language: | English |
| Company: | BIOSYNEX SA |
| 22 Boulevard Sébastien Brant | |
| 67400 ILLKIRCH-GRAFFENSTADEN | |
| France | |
| E-mail: | steinmetz@biosynex.com |
| Internet: | https://www.biosynex.com/ |
| ISIN: | FR0011005933 |
| Euronext Ticker: | ALBIO |
| AMF Category: | Inside information / Issuer activities (acquisitions, sales...) |
| EQS News ID: | 1535213 |
| End of Announcement | EQS News Service |
1535213 13-Jan-2023 CET/CEST
